GELS· Health Care› Drug Manufacturers - Specialty & Generic

Gelteq Limited

Stage 4 · Declining · week 3

As of Oct 22, 2026, Gelteq is in Stage 4, the downtrend phase, now in week 3 (since Oct 7, 2026). It closed at $0.44, 71.6% below its 52-week high and below its 200-day average, which is falling.

Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. More about the company

$0.44

+0.23% today

$4.7M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is GELS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-10-29 → 2026-10-22

S? 42w

S4 44w

2024-10-292026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 42w → S1 1w → S4 44w → S1 3w → S4 2w → S1 4w → S4 4w → S1 1w → S4 2w current

Total tracked: 103 weeks across 9 stage runs.

GELS among Drug Manufacturers - Specialty & Generic67th of 84 by relative strength

All 84 →

Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	CPIXCumberland Pharmaceuticals Inc.	Stage 2 · wk 23	98	+6.8%
2	ETONEton Pharmaceuticals, Inc.	Stage 2 · wk 30	97	−10.1%
3	ANIKAnika Therapeutics Inc.	Stage 2 · wk 15	96	+3.5%
4	IRWDIronwood Pharmaceuticals, Inc. Class A	Stage 3 · wk 3	96	−16.4%
5	TEVATeva Pharmaceutical Industries Limited	Stage 2 · wk 9	95	+3.1%
6	AMRXAmneal Pharmaceuticals, Inc. Class A	Stage 2 · wk 19	95	+5.9%
7	KNSAKiniksa Pharmaceuticals International, plc Class A	Stage 2 · wk 73	95	+6.2%
8	AMLXAmylyx Pharmaceuticals, Inc.	Stage 2 · wk 15	93	−6.6%
…67	GELSGelteq Limited	Stage 4 · wk 3	17	−27.6%

vs 52W High

-71.6%

$0.39 lo$1.53 hi

71.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 3

1w13w26w

Week 3, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-35.3%

200 DMA: $0.67 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.01x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-27.6%

-37.9%

-35.7%

YTD

-48.1%

-65.2%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 3 · Vol 0.01x

2026-10-21S4

Wk 3 · Vol 0.00x

2026-10-20S4

Wk 2 · Vol 0.01x

2026-10-19S4

Wk 2 · Vol 0.05x

2026-10-16S4

Wk 2 · Vol 0.01x

2026-10-15S4

Wk 2 · Vol 0.01x

2026-10-14S4

Wk 2 · Vol 0.01x

2026-10-13S4

Wk 1 · Vol 0.02x

2026-10-12S4

Wk 1 · Vol 0.01x

2026-10-09S4

Wk 1 · Vol 0.01x

2026-10-08S4

Wk 1 · Vol 0.01x

2026-10-07S41→4

Wk 1 · Vol 0.02x

Moving averages & range

50 DMA

$0.57

200 DMA

$0.67

52W High

$1.53

52W Low

$0.39

5D Low

$0.43

Resistance levels (recent highs)

20d High

$0.58

60d High

$0.90

120d High

$1.53

250d High

$1.53

Next resistance

+33.3%

to 20d High

ROE

-42.9%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.5

Gelteq: quick answers

What stage is Gelteq in?

As of Oct 22, 2026, Gelteq (GELS) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 7, 2026 and is in week 3. What the four stages mean

Is Gelteq in an uptrend?

No. Gelteq is in a Stage 4 downtrend. It trades 35.3% below its 200-day average, which is falling.

How far is Gelteq from its 52-week high?

Gelteq closed at $0.44 on Oct 22, 2026, 71.6% below its 52-week high of $1.53. Its 52-week low is $0.39.

How has Gelteq performed over the past year?

As of Oct 22, 2026, Gelteq is down 65.2% over the past year and down 48.1% so far in 2026.

Which sector and industry is Gelteq in?

Gelteq is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.